

providing an agent for inhibiting an interaction between P-selectin and PSGL-1 and between E-selectin and a ligand of E-selectin; and

administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and mimetics of PSGL-1, said agent being effective to inhibit the interaction between P-selectin and PSGL-1 and between E-selectin and a ligand of E-selectin.

Please add the following new claim:

90. A method for treating or inhibiting atherosclerosis in a mammal comprising:  
providing an agent for inhibiting an interaction between P-selectin and PSGL-1; and  
administering said agent to a mammal in need of such treatment so as to cause such inhibition to occur, wherein said agent is selected from the group consisting of PSGL-1, soluble forms of PSGL-1, fragments of PSGL-1, and mimetics of PSGL-1, said agent being effective to inhibit the interaction between P-selectin and PSGL-1.

#### REMARKS

Claims 71-73, 77-81 and 83-89 are currently pending in this application, and claim 90 is newly added.

Applicants believe that the present amendments to the claims now serve to obviate any remaining objections under 35 U.S.C. 112, first paragraph.

Enclosed with this Amendment is a Declaration under Rule 131 by co-inventors Denisa Wagner and Robert Johnson. The Declaration is intended to obviate the rejection under 35 U.S.C. 102(e) and 103(a) on the basis of the Cummings et al. reference. The above identified application has an effective filing date of June 3, 1994. The Cummings et al. reference has an effective filing date of November 16, 1992. Although the actual filing date of the reference is July 21, 1994, the corresponding application is a continuation of a prior application filed on November 16, 1992.